A type of virus known as the human reovirus possesses a remarkable trait: It can replicate inside and kill cancer cells that feature a common mutation (known as an "activated Ras pathway"), while leaving the body's normal cells alone. Now a new study reports that reovirus has the potential to treat certain lung cancer patients, when the reovirus is combined with two other substances known as paclitaxel and carboplatin.
Researchers from The Ohio State University, Georgetown University, and Oncolytics Biotech Inc., a Calgary-based biotechnology company, will present a paper on their findings at the 14th World Conference on Lung Cancer, to be held July 3-7 in Amsterdam, The Netherlands. The annual meeting is organized by the International Association for the Study of Lung Cancer (IASLC). The Denver-based IASLC is the only global organization dedicated to the study of lung cancer. Founded in 1972, the association's membership includes more than 3,000 lung cancer specialists in 80 countries. More than 7,000 participants are expected to attend the 14th World Conference.
The paper is titled "Phase II study of reovirus with paclitaxel (P) and carboplatin (C) in patients with metastatic non-small cell lung cancer (NSCLC) who have Kras or EGFR-activated tumors."
Click "source" for entire article.
Researchers from The Ohio State University, Georgetown University, and Oncolytics Biotech Inc., a Calgary-based biotechnology company, will present a paper on their findings at the 14th World Conference on Lung Cancer, to be held July 3-7 in Amsterdam, The Netherlands. The annual meeting is organized by the International Association for the Study of Lung Cancer (IASLC). The Denver-based IASLC is the only global organization dedicated to the study of lung cancer. Founded in 1972, the association's membership includes more than 3,000 lung cancer specialists in 80 countries. More than 7,000 participants are expected to attend the 14th World Conference.
The paper is titled "Phase II study of reovirus with paclitaxel (P) and carboplatin (C) in patients with metastatic non-small cell lung cancer (NSCLC) who have Kras or EGFR-activated tumors."
Click "source" for entire article.
